Report Categories Report Categories

Report Categories

industry Category

All

Total: 5 records, 1 pages

Global Recombinant Erythropoietin Market 2024 by Company, Regions, Type and Application, Forecast to 2030

date 02 Jan 2024

date Pharma & Healthcare

new_biaoQian Recombinant Erythropoietin

According to our (Global Info Research) latest study, the global Recombinant Erythropoietin market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

USD3480.00

Add To Cart

Add To Cart

Global Recombinant Erythropoietin Drugs Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

date 02 Jan 2024

date Pharma & Healthcare

new_biaoQian Recombinant Erythropoietin Drugs

According to our (Global Info Research) latest study, the global Recombinant Erythropoietin Drugs market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

USD3480.00

Add To Cart

Add To Cart

Global Recombinant Erythropoietin Market 2023 by Company, Regions, Type and Application, Forecast to 2029

date 09 Jan 2023

date Pharma & Healthcare

new_biaoQian Recombinant Erythropoietin

According to our (Global Info Research) latest study, the global Recombinant Erythropoietin market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

USD3480.00

Add To Cart

Add To Cart

Global Recombinant Erythropoietin Drugs Supply, Demand and Key Producers, 2023-2029

date 08 Feb 2023

date Pharma & Healthcare

new_biaoQian Recombinant Erythropoietin Drugs

Erythropoietin (EPO), also known as haematopoietin or haemopoietin, is a glycoprotein cytokine secreted by the kidney in response to cellular hypoxia; it stimulates red blood cell production (erythropoiesis) in the bone marrow. Low levels of EPO (around 10 mU/mL) are constantly secreted sufficient to compensate for normal red blood cell turnover. Common causes of cellular hypoxia resulting in elevated levels of EPO (up to 10 000 mU/mL) include any anemia, and hypoxemia due to chronic lung disease.

USD4480.00

Add To Cart

Add To Cart

Global Recombinant Erythropoietin Drugs Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

date 05 Jan 2023

date Pharma & Healthcare

new_biaoQian Recombinant Erythropoietin Drugs

Erythropoietin (EPO), also known as haematopoietin or haemopoietin, is a glycoprotein cytokine secreted by the kidney in response to cellular hypoxia; it stimulates red blood cell production (erythropoiesis) in the bone marrow. Low levels of EPO (around 10 mU/mL) are constantly secreted sufficient to compensate for normal red blood cell turnover. Common causes of cellular hypoxia resulting in elevated levels of EPO (up to 10 000 mU/mL) include any anemia, and hypoxemia due to chronic lung disease.

USD3480.00

Add To Cart

Add To Cart

industry 02 Jan 2024

industry Pharma & Healthcare

new_biaoQian Recombinant Erythropoietin

According to our (Global Info Research) latest study, the global Recombinant Erythropoietin market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

USD3480.00

addToCart

Add To Cart

industry 02 Jan 2024

industry Pharma & Healthcare

new_biaoQian Recombinant Erythropoietin Drugs

According to our (Global Info Research) latest study, the global Recombinant Erythropoietin Drugs market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

USD3480.00

addToCart

Add To Cart

industry 09 Jan 2023

industry Pharma & Healthcare

new_biaoQian Recombinant Erythropoietin

According to our (Global Info Research) latest study, the global Recombinant Erythropoietin market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

USD3480.00

addToCart

Add To Cart

industry 08 Feb 2023

industry Pharma & Healthcare

new_biaoQian Recombinant Erythropoietin Drugs

Erythropoietin (EPO), also known as haematopoietin or haemopoietin, is a glycoprotein cytokine secreted by the kidney in response to cellular hypoxia; it stimulates red blood cell production (erythropoiesis) in the bone marrow. Low levels of EPO (around 10 mU/mL) are constantly secreted sufficient to compensate for normal red blood cell turnover. Common causes of cellular hypoxia resulting in elevated levels of EPO (up to 10 000 mU/mL) include any anemia, and hypoxemia due to chronic lung disease.

USD4480.00

addToCart

Add To Cart

industry 05 Jan 2023

industry Pharma & Healthcare

new_biaoQian Recombinant Erythropoietin Drugs

Erythropoietin (EPO), also known as haematopoietin or haemopoietin, is a glycoprotein cytokine secreted by the kidney in response to cellular hypoxia; it stimulates red blood cell production (erythropoiesis) in the bone marrow. Low levels of EPO (around 10 mU/mL) are constantly secreted sufficient to compensate for normal red blood cell turnover. Common causes of cellular hypoxia resulting in elevated levels of EPO (up to 10 000 mU/mL) include any anemia, and hypoxemia due to chronic lung disease.

USD3480.00

addToCart

Add To Cart